Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A prop
about
Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A prop
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Conversion to monotherapy with ...... static prostate cancer: A prop
@ast
Conversion to monotherapy with ...... static prostate cancer: A prop
@en
type
label
Conversion to monotherapy with ...... static prostate cancer: A prop
@ast
Conversion to monotherapy with ...... static prostate cancer: A prop
@en
prefLabel
Conversion to monotherapy with ...... static prostate cancer: A prop
@ast
Conversion to monotherapy with ...... static prostate cancer: A prop
@en
P2860
P356
P1433
P1476
Conversion to monotherapy with ...... static prostate cancer: A prop
@en
P2093
Gyeong Eun Min
Hanjong Ahn
P2860
P304
P356
10.3892/OL.2017.6056
P577
2017-04-20T00:00:00Z